Basilea Pharmaceutica AG (SW:BSLN) — Stock Price

CHF52.10 CHF
▲ 0.58% today

Basilea Pharmaceutica AG (SW:BSLN) is currently trading at CHF52.10 CHF, up 0.58% today. Over the past 52 weeks, shares have ranged between CHF44.90 and CHF58.50. This page tracks Basilea Pharmaceutica AG's live share price on the SW exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see BSLN market cap overview.

Basilea Pharmaceutica AG (BSLN) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Basilea Pharmaceutica AG's daily closing share price and trading volume on the SW exchange over the past year, giving a clear view of recent price momentum and liquidity.

Basilea Pharmaceutica AG Income Statement — Revenue, Profit & Earnings by Year

Basilea Pharmaceutica AG's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue CHF232.40 Million CHF208.54 Million CHF157.63 Million CHF147.76 Million CHF148.12 Million
Cost of Revenue CHF39.30 Million CHF38.68 Million CHF26.79 Million CHF26.80 Million CHF24.07 Million
Gross Profit CHF193.10 Million CHF169.86 Million CHF130.84 Million CHF120.96 Million CHF124.05 Million
Research & Development CHF105.90 Million CHF77.14 Million CHF77.85 Million CHF73.80 Million CHF93.16 Million
SG&A CHF35.62 Million CHF31.54 Million CHF33.78 Million CHF30.82 Million CHF29.72 Million
Total Operating Expenses CHF141.50 Million CHF108.69 Million CHF111.64 Million CHF104.62 Million CHF122.88 Million
Operating Income CHF51.60 Million CHF61.18 Million CHF19.20 Million CHF18.54 Million CHF1.19 Million
EBITDA CHF51.60 Million CHF63.13 Million CHF23.18 Million CHF26.21 Million CHF6.72 Million
EBIT — CHF61.70 Million CHF21.61 Million CHF23.11 Million CHF4.27 Million
Interest Expense CHF3.36 Million CHF4.34 Million CHF11.20 Million CHF9.85 Million CHF8.15 Million
Income Before Tax CHF45.90 Million CHF60.26 Million CHF10.46 Million CHF12.10 Million CHF-6.79 Million
Income Tax Expense CHF5.60 Million CHF-17.33 Million CHF10.00K CHF-45.00K CHF37.00K
Net Income CHF40.20 Million CHF77.59 Million CHF10.45 Million CHF12.15 Million CHF-6.83 Million

Basilea Pharmaceutica AG Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Basilea Pharmaceutica AG's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets CHF282.00 Million CHF257.76 Million CHF173.29 Million CHF220.85 Million CHF247.27 Million
Total Current Assets CHF251.73 Million CHF220.91 Million CHF152.15 Million CHF175.36 Million CHF241.07 Million
Cash & Equivalents CHF132.70 Million CHF106.71 Million CHF51.83 Million CHF49.96 Million CHF0.00
Short-term Investments CHF132.70 Million CHF11.00K CHF51.83 Million CHF50.00 Million CHF95.00 Million
Net Receivables CHF63.28 Million CHF56.58 Million CHF27.89 Million CHF61.70 Million CHF64.45 Million
Inventory CHF21.56 Million CHF31.61 Million CHF26.41 Million CHF24.24 Million CHF22.78 Million
Property, Plant & Equipment CHF18.15 Million CHF18.98 Million CHF20.55 Million CHF21.57 Million CHF2.92 Million
Goodwill — — — — —
Total Liabilities CHF154.06 Million CHF176.76 Million CHF183.29 Million CHF241.56 Million CHF305.87 Million
Total Current Liabilities CHF49.22 Million CHF45.56 Million CHF47.59 Million CHF74.85 Million CHF174.41 Million
Long-term Debt CHF75.44 Million CHF95.91 Million CHF95.45 Million CHF131.36 Million CHF94.54 Million
Net Debt CHF71.29 Million CHF-9.03 Million CHF68.71 Million CHF150.57 Million CHF164.00 Million
Total Stockholder Equity CHF127.94 Million CHF81.00 Million CHF-10.00 Million CHF-20.71 Million CHF-58.61 Million
Retained Earnings CHF-882.57 Million CHF-923.29 Million CHF-1.00 Billion CHF-1.01 Billion CHF-1.02 Billion

Basilea Pharmaceutica AG Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Basilea Pharmaceutica AG generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow CHF62.09 Million CHF74.36 Million CHF14.24 Million CHF7.06 Million CHF-32.02 Million
Capital Expenditures CHF2.62 Million CHF1.71 Million CHF1.03 Million CHF3.30 Million CHF860.00K
Free Cash Flow CHF59.47 Million CHF72.65 Million CHF13.21 Million CHF3.75 Million CHF-32.88 Million
Investing Cash Flow CHF-2.86 Million CHF-1.01 Million CHF-1.03 Million CHF91.65 Million CHF3.58 Million
Financing Cash Flow CHF-21.43 Million CHF-13.16 Million CHF-57.30 Million CHF-45.25 Million CHF16.64 Million
Dividends Paid — — CHF57.30 Million — CHF23.21 Million
Stock-Based Compensation CHF5.24 Million CHF5.07 Million CHF4.76 Million CHF3.60 Million CHF4.32 Million
Depreciation CHF3.71 Million CHF4.13 Million CHF3.48 Million CHF3.10 Million CHF2.45 Million
Change in Cash CHF11.79 Million CHF60.24 Million CHF-44.24 Million CHF53.61 Million CHF-654.00K

Basilea Pharmaceutica AG Earnings History — EPS Actual vs. Analyst Estimates

Track Basilea Pharmaceutica AG's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Aug 18, 2026 — — —
Dec 31, 2025 — 1.54 —
Dec 03, 2025 0.00 0.00 —
Aug 19, 2025 1.26 2.12 -40.57%
May 28, 2025 0.00 0.00 —
Feb 18, 2025 2.10 1.71 +22.81%
Nov 27, 2024 0.00 0.00 —
Aug 13, 2024 1.57 1.57 +0.00%